GLORIOUS: GLP-1 Agonist Did Not Meet Primary Endpoint in CABG
In the GLORIOUS trial, exenatide did not decrease mortality or severe organ injury in patients with cardiopulmonary bypass-assisted coronary artery bypass grafting or an aortic valve replacement. ...
